anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a compsn. which is based on a natural substance having an excellent antioxidant power, has no problem with safety, and is useful as an antioxidant or as an external preparation for skin by using an extract of a plant of the genus Dillenia of the family Dilleniaceae as the acting component. SOLUTION: Plants of the genus Dillenia of the family Dilleniaceae include Dillenia indica, Dillenia obata, etc., among which Dillenia indica is esp. pref. Both the raw and dried plants of the genus Dillenia can be used; however, the use of a dried powder or a solvent extract is pref. in terms of usability, preparation of pharmaceuticals, etc. The use of the fruits of Dillenia indica is pref. in the solvent extraction, though other parts can be used. The extract is obtd. e.g. by immersing the plant in an extractant or heating the plant together with an extractant under reflux, separating the plant from the extractant contg. the extract by filtration, and concentrating the extract.
1,153,408. Acylated protein hydrolysates. J. V. MORELLE. 6 Oct., 1967 [13 Oct., 1966], No. 45742/67. Heading C2C. [Also in Division C3] An acylated depeptided protein hydrolysate wherein the acyl radical corresponds to RCO-, R being a C 6-29  aliphatic chain, which is waterinsoluble and lipo-soluble is prepared by hydrolysing a protein to provide a mixture of amino-acids which are acylated with a compound of formula RCOX where X is halogen or hydroxy. In the examples casein is hydrolysed in HCl, the hydrolysate passed through an ion exchange resin to remove peptides and the solution of amino acids then treated with palmitoyl chloride. Other acylated products are obtained by hydrolysing collagen and keratin and acylating the products with palmitoyl chloride, lauryl chloride, stearyl chloride and oleoyl chloride.
<P>PROBLEM TO BE SOLVED: To provide a highly safe and inexpensive anti-aging agent derived from natural products and having high productivity and excellent I type collagen production promoting actions, fibroblast proliferating actions or laminin 5 production promoting actions though daily usable.  <P>SOLUTION: The anti-aging agent is characterized by comprising at least any of Gynura bicolor DC. and an extract thereof as an active ingredient. The extract of the Gynura bicolor DC. is preferably an extract with a mixed solvent of water and ethanol. The type I collagen production promoter is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. The fibroblast proliferation agent is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. The laminin 5 production promoter is characterized by comprising at least any of the Gynura bicolor DC. and the extract thereof as the active ingredient. An external preparation for skin comprises the anti-aging agent and a food and drink for beauty comprises the anti-aging agent.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This is a prospective, one-center, single group, repeated measures, non inferiority study. Forty-five (45) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be evaluated for this study. Each subject will be in the study for six weeks. Clinical benefits will be measured through an assessment of the gait performance. In particular it will test the hypothesis that the NESS L300 Plus System which involves foot drop correction with thigh muscles activation, may achieve walking enhancements not inferior to those gained from using a system that only corrects foot drop (i.e. NESS L300).
The invention relates to a 2,3,4-tri-substituted pyrrole compound and a synthesis method and application thereof. Particularly, under mild conditions, copper-catalyzed isonitrile and allene are subjected to a cyclization reaction, and a simple polysubstituted pyrrole synthesis method is opened up. The compound is shown as the following general molecular formula, wherein R1 and R2 are alkyl groups or aryl groups for providing electrons, and R3 is an alkyl group or halogen. The method is used for synthesizing a series of three-bit aryl sulfone functional group containing 2,3,4-tri-substituted pyrrole compounds for the first time, and the method has wide prospects on the aspect of synthesis and application of a built compound library. Two of the synthesized three-bit aryl sulfone functional group containing 2,3,4-tri-substituted pyrrole compounds are selected for testing in-vitro tumor cell inhibitory activity, and the compound has inhibitory activity on human leukemia cells (HL-60). The formula is shown in the description.
The professional practice of firefighting presents risks specific, especially cardiovascular. In the United States 30% of Firefighter deaths are the result of a myocardial infarction that occurred while on duty. Certain occupational tasks expose firefighters to a higher risk of myocardial infarction (high physical load, inhalation of products). There is no recommendation on how to assess cardiovascular risk in French firefighters. In the absence of consensus, the Loire Departmental Fire and Rescue Service has constructed a scale for collecting cardiovascular risk factors (expert working group) to identify firefighters at high cardiovascular risk. A maintenance visit (mandatory every two years until the age of 38 and then once a year) is the best way to assess this cardiovascular risk, with a biological assessment and an electrocardiogram after the age of 40. If cardiovascular risk factors are present and the cardiovascular risk is high, the resting electrocardiogram should be supplemented by an exercise test. An exercise test can directly or indirectly quantify the endurance capacities of firefighters and reveal cardiac abnormalities sometimes absent at rest. Half of all myocardial infarctions occur without any prior symptomatology and remain totally asymptomatic, discovered during routine examinations. If the risk of myocardial infarction in activity is widely demonstrated to date for firefighters, and the realization of a stress test in those at high cardiovascular risk included in the practice habits, no study has evaluated the contributions and limits of the realization of a stress test in this specific population of firefighters at high cardiovascular risk for the prediction of cardiovascular events.
Peripheral neuropathy often manifests as numbness and tingling in the hands and feet, which may be detrimental to the patients' overall safety and quality of life, thereby causing them to stop or delay treatment. Everyday tasks such as walking, buttoning a shirt, or tying shoes can become challenging. Select chemotherapy agents are known to cause significant peripheral neuropathy. Studies have been performed demonstrating efficacy of using cryotherapy, which causes vasoconstriction, to targeted areas of the body, in relation to paclitaxel. These studies have shown drastic differences between those who receive cryotherapy during treatment and those who do not. There are few studies on the use of cryotherapy in the prevention of peripheral neuropathy with the use of oxaliplatin, which will be undertaken in this study.
OBJECTIVE: This retrospective observational study investigates the heterogeneity of hepatic and pancreatic fat deposition and its implications for metabolic health in individuals with obesity.
METHODS: A total of 706 patients with obesity underwent an MRI to quantify liver and pancreatic fat. Patients were classified into four groups based on fat deposition: no fat (None), fatty pancreas only (NAFPD), fatty liver only (NAFLD), and both conditions (NAFLD+NAFPD). Biochemical profiles, insulin resistance (Homeostatic Model Assessment for Insulin Resistance, HOMA-IR), and β-cell function were analyzed. A series of multiple linear regressions were used to investigate the independent effects of characteristics on glucose, insulin, and C-peptide at 0h. Another multiple linear regression was performed to evaluate the effects of basic characteristics on average liver fat, mean pancreatic fat, and visceral fat.
RESULTS: The majority (76.63%) exhibited both NAFLD and NAFPD, highlighting the heterogeneity of fat deposition among individuals with obesity. Groups with fatty liver displayed significantly higher fasting glucose, insulin, C-peptide, and HOMA-IR levels than those without fatty liver (P < 0.01). Fatty pancreas alone did not significantly influence these metabolic parameters (P > 0.05). This underscores the greater metabolic impact of hepatic fat compared to pancreatic fat.
CONCLUSIONS: The study confirms the complex heterogeneity of fat deposition in obesity, with the fatty liver being a more influential factor in metabolic disturbances than the fatty pancreas. The prevalent co-occurrence of NAFLD and NAFPD in this population underscores the need for targeted management strategies focusing on hepatic fat reduction to mitigate metabolic risk.
DETECTION AND DIAGNOSIS OF CHRONIC KIDNEY DISEASE TO TAKE ACTION AS EARLY AS STAGE 3. The prevalence of chronic kidney disease (CKD) is constantly increasing. The considerable impact of CKD on all-cause mortality, cardiovascular morbidity and on health economy makes it a real public health issue. Early detection helps to prevent progression to advanced stages of the disease. Targeted screening in populations at risk is recommended, with the use of 3 tests: serum creatinine, estimation of GFR and measurement of albumin/creatinine ratios. Once diagnosed, management of CKD involves nephroprotective measures such as blood pressure management, correction of metabolic complications, and prevention of drug toxicity. The general practitioner has a central role in the screening and initial management of CKD.
Placebo cream, 1g will be administered vaginally, initiated at 2 weeks postpartum and continued until 6 months postpartum. Beginning at 2 weeks postpartum, 1g of placebo cream will be administered by participants nightly for 2 weeks then twice weekly to complete 6 months therapy.
PURPOSE: To provide a cosmetic comspn. and medicine compsn. which contain the effective amt. of extensin protein, smooth the texture of the skin and tightens and strengthen the skin. CONSTITUTION: The cosmetics and medicine compsn. contain the effective amt. of the complete extensin protein having a mol.wt. of 100000 to 150000 dalton or the extensin hydrolyzate having a mol.wt. of 100 to 1500 dalton. The extensin is one kind of the plant derived hydroxypurine enriched glycoprotein tightly bonded to the primary cell walls of several kinds of monocot plants and dicotyl plants and relates to the growth of the plants, control, stress reaction, cell-cell recognition and reproductive physiology. The insoluble cross-linked extensin exists in a dissolution form before the extensin is built into the plant cell walls and the soluble extensin precursor is extracted by the salt extraction of the concd. plant suspension pellets or explant homogenate from several kinds of the plants in a growth stage.
BACKGROUND: Poverty can be a robust barrier to HIV care engagement. We assessed the extent to which delivering care for HIV, diabetes and hypertension within community-based microfinance groups increased savings and reduced loan defaults among microfinance members living with HIV.
METHODS: We analyzed cluster randomized trial data ascertained during November 2020-May 2023 from 57 self-formed microfinance groups in western Kenya. Groups were randomized 1:1 to receive care for HIV and non-communicable diseases in the community during regular microfinance meetings (intervention) or at a health facility during routine appointments (standard care). Community and facility care provided clinical evaluations, medications, and point-of-care testing. The trial enrolled 900 microfinance members, with data collected quarterly for 18-months. We used a two-part model to estimate intervention effects on microfinance shares purchased, and a negative binomial regression model to estimate differences in loan default rates between trial arms. We estimated effects overall and by participant characteristics.
RESULTS: Participants' median age and distance from a health facility was 52 years and 5.6 km, respectively, and 50% reported earning less than $50 per month. The probability of saving any amount (>$0) through purchasing microfinance shares was 2.7 percentage points higher among microfinance group members receiving community vs. facility care. Community care recipients and facility care patients saved $44.90 and $25.24 over 18-months, respectively, and the additional amount saved by community care recipients was statistically significant (p = 0.036). Overall and in stratified analyses, loan defaults rates were not statistically significantly different between community and facility care patients.
CONCLUSIONS: Receiving integrated care in the community was significantly associated with modest increases in savings. We did not find any significant association between community-delivered care and reductions in loan defaults among HIV-positive microfinance group members. Longer follow up examination and formal mediation analyses are warranted.
Process for making principle active repulpant, comprises: solubilizing an entire plant powder of Artemisia abrotanum in water/alcohol; separating the soluble and insoluble phases; filtering for concentration of the active fraction; and filtering by sterilizing. An independent claim is included for an active ingredient comprising dry material content of 5-45 g/l, a pH of 3-6 and a sugar content of 3-34 g/l, obtained by the process. ACTIVITY : Dermatological. MECHANISM OF ACTION : Glycerol-3 phosphate dehydrogenase stimulator; Peroxisome proliferator- activated receptor-gamma (PPAR-gamma ) factor expression stimulator. The ability of the principle active to increase the expression of messenger RNA (mRNA) coding for PPAR-gamma was tested in preadipocytes. The results showed that 0.5% composition of the principle active exhibited 76% expression of the mRNA over the control and thus exhibited activation action on the cellular differentiation.
ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is designed to be metered by an apheresis device in apheresis procedures, to prevent platelet activation and coagulation as blood moves throughout the extracorporeal unit (tubing set) in an apheresis procedure. 

The solution is sterile and non-pyrogenic, and it contains no bacteriostatic or antimicrobial agents.

The formulas of the active ingredients are provided in Table 1.

Each 100 mL of ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A contains: (%w/v) Citric Acid, Monohydrate 0.8 g; Dextrose Monohydrate 2.45 g; Sodium Citrate Dihydrate 2.2 g; and Water for Injection.

The polyolefin bag is not made with natural rubber latex or PVC. 

The bag is made from a multilayered film. It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The solution contact layer is an elasticized polyolefin. The bag is nontoxic and biologically inert. The bag-solution unit is a closed system and is not dependent upon entry of external air during administration. The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.
This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
The present invention relates to saccharin zinc (which is disclosed in the formula) which is a novel compound and a synthesis, crystallization and preparation technology. The technology uses saccharin, zinc oxide or zinc carbonate, zinc hydroxide and zinc carbonate hydroxide as raw material. The raw material has a neutralization reaction, which generates the saccharin zinc. After thermal filtration operation and crystallization or recrystallization operation, saccharin zinc crystalline powder or saccharin zinc crystals whose size (a certain number of meshes) accords with the requirement can be prepared. The saccharin zinc belongs to sweetening agents and nutrition enriching agents (zinc intensifying agents) in food additives and medicine for resisting zinc deficiency. Therefore, the saccharin zinc can be widely used in various kinds of processing food and can also be used as animal feed additives.
Specific Aim 1: To test on two study days, one neutral affect and one negative affect day (affect induction) whether negative affect alters brain reinforcement learning in a dopamine system anchored taste reward learning paradigm (a task for prediction error and reward value computation) during functional magnetic resonance brain imaging (fMRI). Hypothesis 1: In response to negative and compared to neutral affect induction, binge eating disorder (BED) and bulimia nervosa (BN) will show increased positive prediction error and taste valuation regression with striatum and insula activation compared to obese (OB) and healthy control (HC) groups. This will be an indication that negative affect excessively activates dopamine related reward circuit response in BED and BN. Specific Aim 2: To study during a food choice paradigm the effects of negative affect on brain circuitry for cognitive control and food valuation. Specific Aim 2a: To study brain circuitry for food valuation in response to neutral or negative affect. Hypothesis 2a: In response to negative and compared to neutral affect induction, BED and BN groups will show greater striatal activation when rating food for taste, compared to OB and HC. This will indicate that BED and BN are associated with increased affect-regulated motivation to approach high calorie foods after negative affect induction and compared to OB and HC. Specific Aim 2b: To study brain control circuitry during food choice in response to neutral or negative affect. Hypothesis 2b: In response to negative and compared to neutral affect induction, BED and BN groups will show increased insula and striatal, but lower dorsolateral prefrontal cortex (DLPFC) activation compared to OB and HC groups. This will indicate that negative affect activates automatic food reward circuit response, but reduces cognitive control circuitry during food choice in BED and BN. Specific Aim 3: To test whether brain activation predicts food intake or negative affect. Specific Aim 3a: To test whether brain activation can predict food intake during a post-fMRI scan test meal. Hypothesis 3a: On negative- versus neutral-affect days, BN and BED will select more food in a post-fMRI scan test meal; lower DLPFC and higher striatal activation during food choice, and higher (prediction error) taste reward activation in insula and ventral striatum will predict greater food intake. Specific Aim 3b: To test whether brain activation during reward learning or food choice predicts negative affect measured by EMA on the study day, as well as measured between study days in the individual's naturalistic environment. Hypothesis 3b: Insula, ventral striatum and DLPFC activation (taste prediction error task, food choice task) during the negative affect condition will predict the intensity of negative affect immediately after fMRI, as well as intensity of negative affect episodes during the days between brain scans in the individual's naturalistic environment, suggesting a neurobiological affective vulnerability.
Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
BACKGROUND: Endotracheal suctioning causes discomfort, is associated with adverse effects, and is resource-demanding. An artificial secretion removal method, known as an automated cough, has been developed, which applies rapid, automated deflation, and inflation of the endotracheal tube cuff during the inspiratory phase of mechanical ventilation. This method has been evaluated in the hands of researchers but not when used by attending nurses. The aim of this study was to explore the efficacy of the method over the course of patient management as part of routine care.
METHODS: This prospective, longitudinal, interventional study recruited 28 subjects who were intubated and mechanically ventilated. For a maximum of 7 d and on clinical need for endotracheal suctioning, the automatic cough procedure was applied. The subjects were placed in a pressure-regulated ventilation mode with elevated inspiratory pressure, and automated cuff deflation and inflation were performed 3 times, with this repeated if deemed necessary. Success was determined by resolution of the clinical need for suctioning as determined by the attending nurse. Adverse effects were recorded.
RESULTS: A total of 84 procedures were performed. In 54% of the subjects, the artificial cough procedure was successful on > 70% of occasions, with 56% of all procedures considered successful. Ninety percent of all the procedures were performed in subjects who were spontaneously breathing and on pressure-support ventilation with peak inspiratory pressures of 20 cm H2O. Rates of adverse events were similar to those seen in the application of endotracheal suctioning.
CONCLUSIONS: This study solely evaluated the efficacy of an automated artificial cough procedure, which illustrated the potential for reducing the need for endotracheal suctioning when applied by attending nurses in routine care.
The invention relates to human antibodies, preferablyrecombinant human antibodies which are specifically bound to humantumour necrotic factor (TNF). The antibodies have high afinity tohTNF, e.g. Kd = 10-8 M or less, low hTNF dissociate velocity, e.g.Koff = 10-3sec-1 or less, and neutralize the hTNF activity invitro and in vivo. Antibody of this invention can be an antibodywith its full length or its antigene-binding part. The antibodiesor parts thereof are applicable for the detection of hTNF and forthe inhibition of hTNF activity, for example in patients sufferingfrom indispositions where the hTNF activity is harmfull. Theinvention also relates to nucleinic acids, vectors and host cellsfor the expression of recombinant human antibodies and to methodsfor their synthetization.77 claims
INTRODUCTION: Immune thrombocytopenia (ITP) affecting pregnancy is a diagnostic and often a therapeutic challenge.
AREAS COVERED: We review the current diagnostic criteria for ITP in pregnancy and the potential utility of laboratory tests. We discuss the impact of ITP on pregnancy outcomes and the effects of pregnancy on patients living with chronic ITP.  We describe the criteria for intervention, the evidence supporting first-line treatment approaches and the therapeutic decisions and challenges in cases refractory to steroids and IVIG. We review the evidence supporting the potential use of thrombopoietin receptor agonists for refractory thrombocytopenia. Finally, we describe the diagnostic, prognostic, and treatment approaches to neonatal ITP and considerations regarding breastfeeding. We searched the terms 'immune thrombocytopenia' and 'pregnancy' on PubMed to identify the relevant literature published before 31 December 2023, including within cited references.
EXPERT OPINION: Decreased platelet production may play a role in pregnancy-related ITP exacerbation. Putative mechanisms include placental hormones, such as inhibin. Although IVIG and prednisone usually suffice to achieve hemostasis for delivery, second-line agents are sometimes required to allow for neuraxial anesthesia. There is growing evidence supporting the use of romiplostim during pregnancy; however, its risk of venous thromboembolism warrants further evaluation.